Garde Capital, Inc. Bio N Tech Se Transaction History
Garde Capital, Inc.
- $1.87 Billion
- Q2 2025
A detailed history of Garde Capital, Inc. transactions in Bio N Tech Se stock. As of the latest transaction made, Garde Capital, Inc. holds 50 shares of BNTX stock, worth $5,154. This represents 0.0% of its overall portfolio holdings.
Number of Shares
50Holding current value
$5,154% of portfolio
0.0%Shares
1 transactions
Others Institutions Holding BNTX
# of Institutions
317Shares Held
43.4MCall Options Held
1.19MPut Options Held
1.29M-
Baillie Gifford & CO7.88MShares$812 Million0.61% of portfolio
-
T. Rowe Price Investment Management, Inc. Baltimore, MD4.83MShares$498 Million0.29% of portfolio
-
Flossbach Von Storch Ag Cologne, 2M4.23MShares$436 Million1.69% of portfolio
-
Primecap Management CO Pasadena, CA3.87MShares$399 Million0.3% of portfolio
-
Dodge & Cox San Francisco, CA3.65MShares$376 Million0.21% of portfolio
About BioNTech SE
- Ticker BNTX
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 242,684,992
- Market Cap $25B
- Description
- BioNTech SE, a biotechnology company, develops and commercializes immunotherapies for cancer and other infectious diseases. The company is developing FixVac product candidates, including BNT111, which is in Phase II clinical trial for advance melanoma; BNT112 that is in Phase I/IIa clinical trial for prostate cancer; BNT113, which is in Phase II...